VJ
Varghese John
Principal Investigator
University of California, Los Angeles
I'm working on
7 months ago
Neurotherapeutics, Brain Drug Delivery, Gene Editing, Medicinal Chemistry
About
At UCLA, Varghese John develops brain‑targeted delivery and disease‑modifying neurotherapeutics. He integrates exosome‑inspired nanovesicles, gene‑editing cargoes, and APP‑pathway modulation with high‑throughput screening, medicinal chemistry, and in vivo models to advance candidates for Alzheimer’s and related neurodegeneration.
Partnering listings
Learn more
University of California, Los Angeles
Brain-permeable sappα enhancer (DDL-110) for multiple sclerosis therapy
DDL-110 is a novel, orally bioavailable, brain-permeable small molecule that enhances soluble amyloid precursor protein alpha (sAPPα) to promote re-myelination in Multiple Sclerosis. UCLA's Drug Discovery Lab has complet...
TechnologyIn developmentUniversity
University of California, Los Angeles
Synthetic exosome delivery platform for CRISPR gene editing in alzheimer's research
A novel lipid nanoparticle, synthetic exosomes, enables delivery of CRISPR RNA across the blood-brain barrier for gene editing in Alzheimer's research, potentially transforming apoE4 to apoE3. This platform is being test...
TechnologyConceptualUniversity
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.
delivered to your inbox.
© 2026 Halo Cures, Inc.